High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
High tumor expression of IDO1 may identify whether a patient is likely to respond to immunotherapy, according to study authors.
Anal Cancer
Standard Therapy for Anal Cancer May Not Affect Long-term Outcomes Among HIV Patients
Healthy HIV-positive patients with anal cancer are treated with standard chemoradiotherapy, but whether this patient population experiences worse outcomes or more severe toxic effects was previously unknown.
Phase 1b/2 Study of DPX-E7 + Cyclophosphamide in HPV-positive Cancers
Researchers are evaluating whether DPX-E7 vaccination is safe and will improve outcomes among patients with HPV-positive head and neck, cervical, or anal cancer.
Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal
Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
Adding Cetuximab to HIV-associated SCCAC Therapy May Reduce LRF
Addition of cetuximab to definitive chemoradiation (CRT) reduces locoregional failure rates but is associated with grade 4 toxicity.
Higher Facility Volume Linked to Improved OS Among Patients With Anal Cancer
Care at radiation oncology centers with a higher volume is associated with improved survival among patients with squamous cell carcinoma of the anal canal.
Patterns in PI3K Signaling Pathway Aberrations Evaluated
Researchers argue that combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated across cancer types.
Incidence Rates for Anal Carcinoma, Adenocarcinoma Have Increased Significantly
Incidence rates (IRs) of anal squamous cell carcinoma (SCC) and squamous carcinoma in situ (CIS) have significantly increased overtime.
HPV Type 16 Seropositivity Common Before Anal Cancer
Human papillomavirus (HPV) type 16 (HPV16) seropositivity is relatively common before anal cancer diagnosis.
Gardasil 9 HPV Vaccine Approved
The FDA has approved Gardasil 9 (9-valent human papillomavirus types) vaccine for the prevention of cervical, vulvar, vaginal, anal cancers.
Next post in General Oncology
